332 related articles for article (PubMed ID: 26210254)
1. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
2. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.
Wang QS; Kong PZ; Li XQ; Yang F; Feng YM
Breast Cancer Res; 2015 Feb; 17(1):30. PubMed ID: 25848863
[TBL] [Abstract][Full Text] [Related]
3. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
Lo PK; Lee JS; Liang X; Sukumar S
Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
[TBL] [Abstract][Full Text] [Related]
4. Dual function of MAZ mediated by FOXF2 in basal-like breast cancer: Promotion of proliferation and suppression of progression.
Yu ZH; Lun SM; He R; Tian HP; Huang HJ; Wang QS; Li XQ; Feng YM
Cancer Lett; 2017 Aug; 402():142-152. PubMed ID: 28577976
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
6. DNA Methylation Affects the SP1-regulated Transcription of FOXF2 in Breast Cancer Cells.
Tian HP; Lun SM; Huang HJ; He R; Kong PZ; Wang QS; Li XQ; Feng YM
J Biol Chem; 2015 Jul; 290(31):19173-83. PubMed ID: 26070560
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal transrepression between FOXF2 and FOXQ1 controls basal-like breast cancer aggressiveness.
Kang LJ; Yu ZH; Cai J; He R; Lu JT; Hou C; Wang QS; Li XQ; Zhang R; Feng YM
FASEB J; 2019 May; 33(5):6564-6573. PubMed ID: 30807702
[TBL] [Abstract][Full Text] [Related]
8. Foxf2 plays a dual role during transforming growth factor beta-induced epithelial to mesenchymal transition by promoting apoptosis yet enabling cell junction dissolution and migration.
Meyer-Schaller N; Heck C; Tiede S; Yilmaz M; Christofori G
Breast Cancer Res; 2018 Oct; 20(1):118. PubMed ID: 30285803
[TBL] [Abstract][Full Text] [Related]
9. FOXF2 deficiency accelerates the visceral metastasis of basal-like breast cancer by unrestrictedly increasing TGF-β and miR-182-5p.
Lu JT; Tan CC; Wu XR; He R; Zhang X; Wang QS; Li XQ; Zhang R; Feng YM
Cell Death Differ; 2020 Oct; 27(10):2973-2987. PubMed ID: 32424142
[TBL] [Abstract][Full Text] [Related]
10. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
11. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.
Hollier BG; Tinnirello AA; Werden SJ; Evans KW; Taube JH; Sarkar TR; Sphyris N; Shariati M; Kumar SV; Battula VL; Herschkowitz JI; Guerra R; Chang JT; Miura N; Rosen JM; Mani SA
Cancer Res; 2013 Mar; 73(6):1981-92. PubMed ID: 23378344
[TBL] [Abstract][Full Text] [Related]
12. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
13. HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.
Pantelaiou-Prokaki G; Mieczkowska I; Schmidt GE; Fritzsche S; Prokakis E; Gallwas J; Wegwitz F
Clin Epigenetics; 2022 Jan; 14(1):7. PubMed ID: 35016723
[TBL] [Abstract][Full Text] [Related]
14. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
15. The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer.
Lo PK
PRAS Open; 2017; 1():. PubMed ID: 29046905
[TBL] [Abstract][Full Text] [Related]
16. Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor.
Kong PZ; Yang F; Li L; Li XQ; Feng YM
PLoS One; 2013; 8(4):e61591. PubMed ID: 23620774
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between epithelial-mesenchymal transition and basal cell-like phenotype in breast cancer].
Wu WX; Zhang YP; Wen XW; Lu N; Tang ZY; Zhang Y; Wang Z; Wang W; Yang HJ
Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):519-23. PubMed ID: 20021961
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that have undergone BMP2/RUNX2 signaling pathway induction.
Tan CC; Li GX; Tan LD; Du X; Li XQ; He R; Wang QS; Feng YM
Oncotarget; 2016 Nov; 7(48):79688-79705. PubMed ID: 27806311
[TBL] [Abstract][Full Text] [Related]
19. MiR-200c inhibits metastasis of breast tumor via the downregulation of Foxf2.
Zhang T; Wan JG; Liu JB; Deng M
Genet Mol Res; 2017 Aug; 16(3):. PubMed ID: 28829888
[TBL] [Abstract][Full Text] [Related]
20. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
Li Y; Yang W; Yang Q; Zhou S
Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
